deltatrials
Completed PHASE4 INTERVENTIONAL NCT00520650

Health Evaluation of Abilify Long-term Therapy (HEALTH)

Sponsor: Taiwan Otsuka Pharm. Co., Ltd

Conditions Schizoaffective Disorder Schizophrenia
Interventions Aripiprazole
Updated 7 times since 2017 Last updated: Dec 15, 2009 Started: Aug 31, 2006 Primary completion: Apr 30, 2009 Completion: Apr 30, 2009
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Schizoaffective Disorder and Schizophrenia and is currently completed. Taiwan Otsuka Pharm. Co., Ltd leads this study, which shows 7 recorded versions since 2006 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Study Description(click to expand)

Further study details as provided by Taiwan Otsuka Pharmaceutical Co., Ltd.

Further study details as provided by Taiwan Otsuka Pharmaceutical Co., Ltd.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – ~Dec 2025 · 3 months · monthly snapshotCompleted~Dec 2025 – present · 4 months · monthly snapshotCompleted

Change History

7 versions recorded

  1. Dec 2025 — Present [monthly]

    Completed PHASE4

  2. Sep 2025 — Dec 2025 [monthly]

    Completed PHASE4

  3. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE4

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  5. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE4

▶ Show 2 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE4

  2. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE4

    First recorded

Aug 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Taiwan Otsuka Pharm. Co., Ltd
Data source: Taiwan Otsuka Pharm. Co., Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations